{
  "primary": "VCP",
  "_delete_interactor": false,
  "validation_note": "The role of VCP in clearing TDP-43 aggregates is strongly supported by the literature. It functions as an ATPase to disaggregate and clear insoluble TDP-43 from the nucleus and also aids in the turnover of cytoplasmic TDP-43. The input data is accurate.",
  "direction": "primary_to_main",
  "arrow": "regulates",
  "intent": "disaggregation",
  "functions": [
    {
      "function": "TDP-43 Aggregate Clearance",
      "arrow": "activates",
      "cellular_process": "VCP/p97, an ATPase, utilizes energy from ATP hydrolysis to extract ubiquitinated TDP-43 from insoluble aggregates, primarily in the nucleus. This disaggregase activity is essential for nuclear protein homeostasis.",
      "effect_description": "VCP-mediated clearance is critical for resolving pathological TDP-43 inclusions. Pathogenic VCP mutations impair this process, leading to aggregate accumulation, whereas pharmacological activation of VCP's ATPase activity enhances clearance.",
      "biological_consequence": [
        "Formation of insoluble nuclear TDP-43 aggregates → VCP recruitment to aggregates → VCP ATPase-driven disaggregation → Extraction of ubiquitinated TDP-43 from aggregates → Degradation of cleared TDP-43 by the proteasome → Restoration of nuclear proteostasis"
      ],
      "specific_effects": [
        "Pharmacologic activation of VCP's D2 ATPase activity enhances the clearance of insoluble intranuclear TDP-43 aggregates.",
        "Cells with pathogenic VCP mutations or those treated with a VCP inhibitor exhibit decreased clearance of TDP-43 aggregates.",
        "VCP function is essential for maintaining nuclear protein homeostasis."
      ],
      "evidence": [
        {
          "paper_title": "VCP activator reverses nuclear proteostasis defects and enhances TDP-43 aggregate clearance in multisystem proteinopathy models",
          "relevant_quote": "Consistent with a loss of nuclear VCP function, cells harboring MSP variants or cells treated with VCP inhibitor exhibited decreased clearance of insoluble intranuclear TDP-43 aggregates. Moreover, we identified 4 compounds that activate VCP...where pharmacologic VCP activation appears to enhance clearance of insoluble intranuclear TDP-43 aggregate.",
          "doi": "10.1172/JCI169039",
          "authors": "Phan JM, Creekmore BC, Nguyen AT, Bershadskaya DD, Darwich NF, Mann CN, Lee EB",
          "year": 2024,
          "journal": "J Clin Invest",
          "pmid": "38787785"
        },
        {
          "paper_title": "Cdc48/VCP and Endocytosis Regulate TDP-43 and FUS Toxicity and Turnover",
          "relevant_quote": "Cdc48 physically interacts and colocalizes with TDP-43, as does VCP, in ALS patient tissue... these data suggest a role for Cdc48/VCP-facilitated endocytosis in regulating TDP-43 and FUS turnover and thus toxicity.",
          "doi": "10.1128/MCB.00256-19",
          "authors": "Blue RE, Ruan K, Arakhamia T, Wilson BO, Xia R, Munsell EV, Johnson BS, Gardner RG, Chalphin AV, Weitzman MD, Shorter J, Bonini NM, S-R, Leung AKL",
          "year": 2020,
          "journal": "Mol Cell Biol",
          "pmid": "31767634"
        }
      ],
      "pmids": [
        "38787785",
        "31767634"
      ],
      "interaction_effect": "activates",
      "interaction_direction": "primary_to_main",
      "function_effect": "activation"
    }
  ],
  "mechanism": "VCP/p97, an ATPase, utilizes energy from ATP hydrolysis to extract ubiquitinated TDP-43 from insoluble aggregates, primarily in the nucleus. This disaggregase activity is essential for nuclear protein homeostasis.",
  "effect": "VCP-mediated clearance is critical for resolving pathological TDP-43 inclusions. Pathogenic VCP mutations impair this process, leading to aggregate accumulation, whereas pharmacological activation of VCP's ATPase activity enhances clearance.",
  "summary": "TDP43 activates VCP to modulate tdp-43 aggregate clearance, ultimately affecting restoration of nuclear proteostasis.",
  "evidence": [
    {
      "paper_title": "VCP activator reverses nuclear proteostasis defects and enhances TDP-43 aggregate clearance in multisystem proteinopathy models",
      "relevant_quote": "Consistent with a loss of nuclear VCP function, cells harboring MSP variants or cells treated with VCP inhibitor exhibited decreased clearance of insoluble intranuclear TDP-43 aggregates. Moreover, we identified 4 compounds that activate VCP...where pharmacologic VCP activation appears to enhance clearance of insoluble intranuclear TDP-43 aggregate.",
      "doi": "10.1172/JCI169039",
      "authors": "Phan JM, Creekmore BC, Nguyen AT, Bershadskaya DD, Darwich NF, Mann CN, Lee EB",
      "year": 2024,
      "journal": "J Clin Invest"
    },
    {
      "paper_title": "Cdc48/VCP and Endocytosis Regulate TDP-43 and FUS Toxicity and Turnover",
      "relevant_quote": "Cdc48 physically interacts and colocalizes with TDP-43, as does VCP, in ALS patient tissue... these data suggest a role for Cdc48/VCP-facilitated endocytosis in regulating TDP-43 and FUS turnover and thus toxicity.",
      "doi": "10.1128/MCB.00256-19",
      "authors": "Blue RE, Ruan K, Arakhamia T, Wilson BO, Xia R, Munsell EV, Johnson BS, Gardner RG, Chalphin AV, Weitzman MD, Shorter J, Bonini NM, S-R, Leung AKL",
      "year": 2020,
      "journal": "Mol Cell Biol"
    }
  ],
  "interaction_effect": "regulation",
  "_validation_metadata": {
    "validated": true,
    "validator": "arrow_effect_validator",
    "corrections_applied": 3
  },
  "_arrow_validated": true,
  "arrow_notation": "TDP43 <--regulates-- VCP:",
  "protein_a": "TDP43",
  "protein_b": "VCP",
  "discovered_in_query": "TDP43",
  "first_discovered": "2025-11-23T10:09:34.087516Z",
  "last_updated": "2025-11-23T10:09:34.087516Z"
}